API
< Back to situation

[REVISION HISTORY]

South Korean pharmaceutical and biotech industry development

1 recorded revision of this situation.

What changed

2026-11-09 02:34 UTC → 2026-11-13 01:11 UTC · added removed

The South Korean government, through the Ministry of Health and Welfare and the Ministry of SMEs and Startups, announced a strategic plan to foster 200 “K-pharmaceutical and bio frontier companies” by 2030. This initiative provides support for small and medium-sized enterprises across various stages, including drug candidate discovery, clinical trials, and global expansion. The plan includes annual selections in sectors such as new drug development, medical devices, and biomaterials, supported by specialized R&D banks providing significant investment and commercialization guarantees. In line with these growth objectives, South Korean firms such as Alteogen and Jeil Pharmaceutical have begun seeking intensified their pursuit of international opportunities. partnerships. At the BIO-Europe 2026 conference in Cologne, Germany, these approximately 210 South Korean companies participated, making South Korea the fourth largest national delegation at the event. The Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) engaged with international organizations, such as the U.S. Biotechnology Innovation Organization (BIO), to discuss regulatory cooperation and business matching. Specific companies highlighted their assets during these forums. Alteogen promoted specific assets, including its Hybrozyme subcutaneous injection platform and its multi-target macular degeneration drug candidates candidate, ALTS-OP01, aiming to transition from a platform provider to a drug licensor. Jeil Pharmaceutical sought collaborations for its dual SGLT1/SGLT2 inhibitor, JP-2266, its SOS1 inhibitor, JP9441, and its diabetes treatments, to secure global partnerships combination therapy, Duglow. Domestically, at BioPlus-Interphex Korea 2026, the Hwasun Chonnam National University Hospital Advanced Precision Medical Industry Support Center facilitated over 100 consultations for regional firms, including NPK Bio, Kablu Bio, and technology licensing deals. VS Pharmtech, regarding manufacturing and investment.

Versions

  1. 2026-11-13 01:11 UTC South Korean pharmaceutical and biotech industry development
  2. 2026-11-09 02:34 UTC South Korean pharmaceutical and biotech industry development

Select a version to see what changed compared to the one before it.